minactivin

secreted by monocytes; MW 66,000; inactivates the human urokinase-type plasminogen activators having MW 52,000 & 36,000; no other info available 12/83

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 02/01/1987 - "Human monocyte minactivin specifically inhibited HPA52 activity in cancer tissue homogenates and in colon cancer cell supernatants, an effect that was greatly enhanced by preincubation with plasminogen, indicating that the predominant form of HPA52 in tissue and the form that is secreted in vitro is the proenzyme. "
2.	Colonic Neoplasms (Colon Cancer) 02/01/1987 - "Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation." 02/01/1987 - "Human monocyte minactivin specifically inhibited HPA52 activity in cancer tissue homogenates and in colon cancer cell supernatants, an effect that was greatly enhanced by preincubation with plasminogen, indicating that the predominant form of HPA52 in tissue and the form that is secreted in vitro is the proenzyme. "

Related Drugs and Biologics

1.	Urokinase-Type Plasminogen Activator (Urokinase)
2.	Plasminogen
3.	Enzyme Precursors (Zymogens)